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Antiretroviral therapy has dramatically improved the lives of human immunodeficiency
virus 1 (HIV-1) infected individuals. Nonetheless, HIV-associated neurocognitive disorders
(HAND), which range from undetectable neurocognitive impairments to severe dementia,
still affect approximately 50%of the infected population, hampering their quality of life. The
persistence of HAND is promoted by several factors, including longer life expectancies,
the residual levels of virus in the central nervous system (CNS) and the continued
presence of HIV-1 regulatory proteins such as the transactivator of transcription (Tat)
in the brain. Tat is a secreted viral protein that crosses the blood–brain barrier into the
CNS, where it has the ability to directly act on neurons and non-neuronal cells alike.
These actions result in the release of soluble factors involved in inflammation, oxidative
stress and excitotoxicity, ultimately resulting in neuronal damage. The percentage of
methamphetamine (MA) abusers is high among the HIV-1-positive population compared
to the general population. On the other hand, MA abuse is correlated with increased
viral replication, enhanced Tat-mediated neurotoxicity and neurocognitive impairments.
Although several strategies have been investigated to reduce HAND and MA use, no
clinically approved treatment is currently available. Here, we review the latest findings of
the effects of Tat and MA in HAND and discuss a few promising potential therapeutic
developments.
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INTRODUCTION
The human immunodeficiency virus 1 (HIV-1) affects 35.3 million individuals worldwide
(UNAIDS). The entry of the virus in the central nervous system (CNS) early during infection,
and the relatively low penetration of current antiretroviral therapies (ART) in the brain, results
in neurological complications collectively called HIV-associated neurocognitive disorders (HAND;
Davis et al., 1992; reviewed in Gray et al., 1993; reviewed in Owen and Khoo, 2004; reviewed in
Miller et al., 2008; Valcour et al., 2012; reviewed in Spudich, 2013). HAND can be subdivided into
asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and severe
forms of HIV-associated encephalitis/dementia (HAD). Patients affected with ANI and MND score
poorly in neuropsychological testing, but their everyday functioning is only minimally impacted. In
contrast, HAD patients experience severe neurological failure that severely hampers their daily lives.
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Characteristic HAD symptoms include inflammation of the
brain, decline in cognitive functions (memory, concentration,
attention, and executive control), reduced motor function (loss of
dexterity and coordination) and the mimicking of other dementia
symptoms, such as in Alzheimer’s and Parkinson’s diseases. In
addition, HAD patients present comorbid behavioral changes
such as unipolar depression (apathy and loss of motivation),
fatigue and social withdrawal (reviewed in Antinori et al., 2007).
ART has considerably decreased the early occurrence of HAD, but
the diagnosis of moderate neurocognitive impairments continues
to increase (reviewed in Cisneros and Ghorpade, 2012). This
increase is primarily attributed to longer life spans, the long-term
toxicity of ART, and the development of resistance to therapy
(reviewed inPardo et al., 2001; reviewed in Lv et al., 2015; reviewed
in Underwood et al., 2015).
The best accepted model to explain how HIV-1 gains access
to the CNS is the “Trojan horse” hypothesis, in which infected
monocytes and macrophages cross the blood–brain barrier
(BBB) and subsequently infect non-neuronal cells including
perivascular macrophages and glial cells (reviewed in Haase,
1986). Macrophages and microglia are the main supporters of
viral replication in the brain (reviewed in Bagashev and Sawaya,
2013), whereas astrocytes are susceptible to HIV-1 infection but
alone are not thought to support productive infection (reviewed
in Bagashev and Sawaya, 2013). Pericytes have also been suggested
as cells that may become infected by HIV-1, although at low
levels, and be modified as a result of the presence of HIV-1 in the
brain, thereby further contributing to BBB disruption (Nakagawa
et al., 2012). Even though HIV-1 does not infect neurons, a major
aspect of HAND is neuronal damage and apoptosis (reviewed
in Kovalevich and Langford, 2012). Two mechanistic models of
toxicity have been proposed: direct and indirect (or “bystander”;
reviewed in Lindl et al., 2010). The direct model suggests that viral
proteins released from infected cells cause neuronal death through
a direct interactionwith neurons. The indirectmodel proposes the
death of neurons through the activity of soluble factors released
as a result of inflammatory responses to viral particles or changes
in the brain environment by non-neuronal cells. Regardless
of the means, among the consequences of HIV infection is
synaptodendritic injury to neurons that closely correlates to the
occurrence and severity of neurocognitive disorders (reviewed in
Ellis et al., 2007).
This synaptodendritic injury may be driven by viral replication
in non-neuronal cells and is defined by structural and chemical
changes occurring at neuronal synapses, resulting in a disturbance
of communication between neurons responsible for behaviors
such as memory, learning, and executive functions (reviewed
in Ellis et al., 2007; reviewed in Nath and Steiner, 2014).
Experimental studies in mice, monkeys or in human brain
tissues confirm that exposure to HIV and the transactivator
of transcription (Tat) protein induce alterations in neuronal
morphology (reviewed in Ellis et al., 2007; Bertrand et al.,
2014; reviewed in Nath and Steiner, 2014). These morphological
changes associated with synaptodendritic injury may involve
mitochondrial dysfunction (Greenwood et al., 2007). Notably,
synaptodendritic injury may be reversible depending on the
degree of injury (an example of “brain plasticity”; reviewed in
Ellis et al., 2007). Accordingly, the addition of neuroprotective and
regenerative factors to ART has been proposed to reduce HAND
progression (reviewed in Ellis et al., 2007).
Among the viral proteins that play a role in neuropathogenesis,
Tat, is a significant contributor. Although the main function of
Tat is to regulate HIV-1 transcription, it has also been implicated
in the dysregulation of inflammatory processes, induction
of oxidative stress, excessive activation of neurotransmitters,
modulation of apoptotic pathways, and irregular neurogenesis
(see “Tat Neurotoxicity”, below). Indeed, elevated levels of Tat
mRNA are commonly found in post-mortem brain samples from
individuals with HAD (Wesselingh et al., 1993; Wiley et al., 1996;
Hudson et al., 2000).
Beyond this, drug abuse correlates with an increased
risk of exposure to HIV-1. The world drug report of 2014
(UNAIDS) describes that the prevalence of HIV infection among
injecting drug users is 22–50 times higher than in the general
population, depending on the country. The abuse of drugs
largely prevalent in the US and worldwide, particularly the
strong psychostimulant methamphetamine (MA), is correlated
with increased neurotoxicity and immune system impairments,
with a consequential exacerbation of HAND (Potula and
Persidsky, 2008). It has been demonstrated in human and
animal studies that the neurotoxicity caused by MA and Tat (or
HIV-1 infection), results in greater cognitive and locomotor
impairments than with either MA or Tat (or HIV-1) alone (see
“Tat and Methamphetamine Neurotoxicity”).
This review will focus on the effects of Tat, MA, and their
concerted effects in the CNS. Given that no treatment is yet
available against the neurotoxic activity of Tat (Mediouni et al.,
2012), or the additive detrimental effects of both Tat and MA,
we will conclude with a discussion of some promising candidates
emerging in the literature.
TAT NEUROTOXICITY
The early HIV-1 gene product, Tat, is an 86–103 amino
acid protein, divided in six functional regions (Kuppuswamy
et al., 1989; Figure 1A). Tat binds through its basic domain
to the 50-terminal region of HIV mRNA’s stem-bulge-loop
structure transactivation response element (TAR), and recruits the
positive transcription elongation factor b (P-TEFb) to promote
transcriptional elongation from the viral promoter (Cann et al.,
1985). In addition to its key role in HIV-1 transcription
amplification, Tat can be transported and secreted by HIV-1
infected cells, and can cross the BBB. Once in the brain, non-
infected cells may uptake Tat passively or via interaction with
membrane receptors (reviewed in Li et al., 2009). Immunostaining
patterns suggest that Tat can be found in the cytoplasm of
perivascular macrophages, microglia nodules and in glial cells,
but also in the nuclei of some neurons and oligodendrocytes.
These data suggest that Tat can be taken up by all CNS cells and
potentially exert its effects distally from HIV-1 replication sites
(Del Valle et al., 2000; Hudson et al., 2000; Liu et al., 2000). As
noted above, the neurotoxic activity of Tat comes from both direct
action on neurons and by altering the release of different soluble
factors from surrounding non-neuronal cells resulting in neuronal
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FIGURE 1 | Tat HIV clades and HAND. (A) Conservation of the nucleotide sequences of Tat representative of the main HIV-1 clades (A–D and the circulating
recombinant CRF_ AE/AG), brain derived isolates from non-demented HIV/AIDS individuals (ND sequences from Boven et al., 2007) and from individuals with HIV
associated dementia [HAD sequences from Boven et al. (2007) and Thomas et al. (2007)]. Tat is encoded by two exons, divided into six functional regions. Region I
(residues 1–21) is a proline-rich region, shown to protect Tat from degradation (Campbell and Loret, 2009; Caputo et al., 2009). Region II (residues 22–37) has seven
conserved cysteines except for subtype C (which has 31C!31S) and the recombinant CRF_AE and CRF_AG (with more cysteines). Any mutation of these cysteines
(except 31C) leads to loss of the transactivation activity (Kuppuswamy et al., 1989; Jeang et al., 1999). Region III (residues 38–48) has a conserved 38F(x)2KxLGISY
motif. Mutation of 41K results in loss of transactivation (Kuppuswamy et al., 1989; Peloponese et al., 2000). 38F is conserved in Tat sequences and shown to be
involved in binding to tubulin, resulting in apoptosis (Chen et al., 2002). Region I, II, and III constitute the minimal activation domain, which binds to cyclin T1. Region
IV (residues 49–59) is rich in basic residues with the conserved sequence 49RKKRRQRRRPP. This domain is responsible for Tat’s interaction with TAR and is also a
nuclear and nucleolar signal. Mutations in this domain results in loss of transactivation (Hauber et al., 1989) and delocalization of Tat from the nucleolus (Mousseau
et al., 2012). The regions II as well as IV and Tat peptides covering the 31–61 amino acid region (in gray) were demonstrated to be neurotoxic (Mabrouk et al., 1991;
Sabatier et al., 1991; Philippon et al., 1994; Weeks et al., 1995; Vives et al., 1997; Jones et al., 1998; Jia et al., 2001; Turchan et al., 2001; Self et al., 2004; Aksenov
et al., 2006; Daily et al., 2006; Li et al., 2008; Mishra et al., 2008). Region V (residues 60–72) is the glutamine-rich region and was shown to be involved in apoptosis
of lymphocytes T (Campbell et al., 2004). Regions I to V are encoded by exon I. Region VI is encoded by the second exon and contain a conserved RGD motif, found
only in subtypes B and D. Predicted stop codon is indicated by an asterisk (*). % P: percentage of HIV-1 infected individuals in 2004–2007 with the indicated type of
clade (Hemelaar et al., 2011). (B) Number of publications comparing the activity of HIV-1 clade B to other clades in the indicated neurotoxic activities.
or synaptodendritic injury. Brain histological changes similar to
those observed in HAD patients have been observed in different
mousemodels expressingHIV-1 Tat (reviewed in Rappaport et al.,
1999; Bruce-Keller et al., 2003; Chauhan et al., 2003; Kim et al.,
2003). A positive correlation has also been shown between the
levels of Tat mRNA transcripts and HIV- and simian human
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immunodeficiency virus (SIV)-induced encephalitis (Hudson
et al., 2000).
The majority of the studies investigating neurotoxicity
mediated by Tat demonstrated that the neurotoxic domain
comprised part of the cysteine-rich/ZnF domain, the core
and the basic domain of the protein (Figure 1A). Studies on
HIV-1 clade B demonstrated the strong contribution of the
highly conserved cysteine-rich/ZnF domain to neurotoxicity
(Aksenov et al., 2009). In fact, studies carried out using other
clades reported lesser neurotoxicity, which was attributed to
differences in the sequence of the cysteine-rich/ZnF domain
(Mishra et al., 2008). A summary of these findings is shown
in Figure 1B. Interestingly, Tat from HIV-1 isolates found in
patients with HAD exhibited higher neurotoxic potential than
Tat isolated from non-HAD patients (Figure 1B). This suggests a
relationship between characteristics of the brain environment and
the selection of neurotoxic isolates, and validates the relevance
of using Tat from virus present in HAD-positive individuals
to study Tat activity, rather than laboratory adapted viruses.
Regrettably, most of the studies on Tat to date do not address
potential differences between the neurotoxic activity of Tat
expressed upon transfection of eukaryotic cells and recombinant
Tat produced in bacteria. Of the few studies that have offered
such comparisons, either no differences were observed (Zauli
et al., 2000; Koller et al., 2001), or higher toxicity was detected
with transfected Tat when equivalent concentrations of both were
examined (Li et al., 2008). These results could be explained by
differences on the folding of Tat protein in vitro, and in vivo, or by
differences of post-transcriptional modifications of Tat between
eukaryotic and prokaryotic cells. There is also the possibility that
the recombinant protein suffers some degradation when added
to cell cultures, resulting in reduced activity.
Tat and Neurotransmitters Modulation
The effects of Tat on neurotransmission have been largely
studied on the glutamatergic (GLUTergic) and dopaminergic
(DAergic) systems. Glutamate is an excitatory neurotransmitter
essential for learning, memory, and synaptic plasticity (reviewed
in Rahn et al., 2012), and has been shown to regulate drug
reward (Campbell et al., 2004; Mishra et al., 2008). However,
excessive glutamate causes “glutamate excitotoxicity” leading
to neuron death (reviewed in Rahn et al., 2012). Tat protein
impairs glutamate reuptake by astrocytes (Zhou et al., 2004)
and increases microglial glutamate release (Gupta et al., 2010),
elevating extracellular glutamate levels. The down-regulation of
the excitatory amino acid transporter-2 (EAAT-2) involved in
the reuptake of glutamate and the stimulation of the glutamate
release from microglial cells, was also reported in the presence of
Tat (Rumbaugh et al., 2007). More directly, Tat further promotes
glutamate excitotoxicity by directly binding to or phosphorylating
the glutamateN-methyl-D-aspartate (NMDA) receptor (Haughey
et al., 2001; Prendergast et al., 2002; Song et al., 2003). TheCys30–31
motif in the clade B Tat protein interacts with the extracellular
domain of the NR1 subunit of the NMDA receptor (Li et al.,
2008). The mutation of Cys31 into Ser31 in HIV-1 Tat expressed
by HIV-1 clade C and/or polymorphisms of the NMDA receptor
subunits could explain the lesser neurotoxic activity of clade
C Tat (Mishra et al., 2008; Rao et al., 2008; King et al., 2010;
Eugenin et al., 2011). Interestingly, a recent study showed that
Tat potentiates NMDA-evoked increases in intracellular Ca2+
concentration ([Ca2+]i) via the low-density lipoprotein receptor-
related protein (LRP) and activation of Src tyrosine kinase,
and mediated by a GTPase RhoA and Rho-associated protein
kinase (ROCK; Krogh et al., 2015). However, potentiation is
rapidly followed by a gradual adaptation and decrease of [Ca2+]i,
resulting in neuronal protection from excessive calcium influx
(Krogh et al., 2014, 2015). This suggests that even if Tat activates
the NMDA receptor at picomolar concentrations (Li et al., 2008),
Tat-mediated neurotoxicity throughNMDAmay require a certain
activation threshold. Consistent with this, Tat inhibits glutamate-
induced variation in intracellular Ca2+ in astrocytes (Koller et al.,
2001), resulting in protection from death. Several studies using
astrocyte cells to study the effects of Tat in HAND and/or the
response to drugs of abuse may take advantage of this protection
from death (Chauhan et al., 2003; Kim et al., 2003; Thomas et al.,
2007; Mediouni et al., 2015).
The neurotransmitter dopamine (DA) plays important roles in
motor control, motivation, reward, arousal, cognition, executive
functions, and maternal behaviors (reviewed in Nutt et al.,
2015). The impairment of DA neuronal functions correlates
with early stage of HIV infection (Berger et al., 1994). Tat
perturbs the normal signaling of DA transmission by inhibiting
the activity of theDA transporter (DAT) through a concentration-
dependent allosteric mechanism (Chan and Kantor, 2009; Zhu
et al., 2009) without affecting DA release (reviewed in Turowski
andKenny, 2015). This prevents astrocytes frombufferingDAand
from triggering the release signal for neuroprotective molecules
mediated through DAT (Silvers et al., 2007; Zhu et al., 2009,
2011; Perry et al., 2010; Miyazaki et al., 2011; Midde et al.,
2012, 2013). Tat also inhibits the vesicularmonoamine transporter
(VMAT2) and the expression of tyrosine hydroxylase (TH, the
rate limiting enzyme in DA biosynthesis), thus amplifying DA
neurotoxicity (Zauli et al., 2000; reviewed in Everall et al., 2005;
Midde et al., 2012, 2013; Theodore et al., 2012). These findings,
associated with disturbances in the DAergic system are observed
both in humans and in animals models (reviewed in Koutsilieri
et al., 2002a,b; Jenuwein et al., 2004) and may have implications
in the development of symptoms commonly observed in both
Parkinson’s disease and in HAND (reviewed in Koutsilieri et al.,
2002a,b).
Tat and Oxidative Stress
Low- and short-term reactive oxygen species (ROS) such as
hydrogen peroxide (H2O2) and nitric oxide (NO) are important to
cellular physiology as they participate in cell signaling in several
biological processes (reviewed in D’Autreaux and Toledano, 2007;
reviewed in Erusalimsky and Moncada, 2007). In the brain,
ROS and NO interact in many ways to induce activation of
brain cell glial subpopulations (Saha and Pahan, 2006a,b) and
promote neuronal activity (Atkins and Sweatt, 1999). However,
sustained high levels of ROS induce lipid peroxidation, protein
oxidation and impairment of DNA synthesis and fidelity, events
collectively called “oxidative stress” (reviewed in Pocernich et al.,
2005; reviewed in Schieber and Chandel, 2014). Markers of
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oxidative stress are detected in brain and cerebrospinal fluid
(CSF) of HAD patients (reviewed in Pocernich et al., 2005).
Oxidative stress and neurodegeneration are secondary to glial
activation and occur when ROS and NO approach inflammatory
levels.
Tat has been shown to alter the production of ROS, in
particular of reactive nitrogen species, leading to a loss of neuronal
activity. Several studies in vivo and in vitro have shown an
increase in the expression of intracellular NO synthase (NOS2)
in brain cell subsets, resulting in an increase of NO following
Tat exposure (Philippon et al., 1994; Bukrinsky et al., 1995; Jones
et al., 1998; Liu et al., 2002; Kim et al., 2015). Excess NO may
induce glutamate release from astrocytes (Bal-Price et al., 2002),
thereby further hyperactivating NMDA receptors on neurons
that, in turn, triggers further ROS-associated neuronal death
(Capone et al., 2013). Moreover, in astrocytes exposed to Tat,
a NOS2-dependent mechanism up-regulates adhesion molecules
that induce recruitment of monocytes and viral replication (Song
et al., 2011), consistent with the observation that elevated NO
levels are associated with increased HIV-1 replication (reviewed
in Torre et al., 2002). In parallel, Tat can induce the expression
of factors that regulate its own activity over the HIV LTR,
such as Nrf2 (nuclear erythroid 2 related factor 2). Nrf2 is a
critical regulator of genes involved in the antioxidant response.
Although the induction of Nrf2 by Tat is not enough to
protect cells from oxidative stress in MAGI cell systems (Zhang
et al., 2009), the ROS-induced expression in astrocytes has been
reported to show a strong neuroprotective effect (Bell et al.,
2011).
Other markers of oxidative stress such as protein carbonyl
formation and lipid peroxidation in vitro and in vivo, as well as
perturbation of the cellular antioxidant response have also been
linked to Tat expression (Flores et al., 1993; Milani et al., 1996;
Borgatti et al., 1998; Haughey et al., 1999, 2004; Choi et al., 2000;
Aksenov et al., 2001; Richard et al., 2001; Pocernich et al., 2004;
Agrawal et al., 2012; Kim et al., 2015).
Tat and Blood–Brain Barrier Disruption
The BBB is composed of brain endothelial cells connected by
tight junctions and is supported by astrocytes. Tat and specific Tat
peptides can passively cross the BBB in both directions (Banks
et al., 2005). Tat can also use different mechanisms to decrease
the expression of tight junction proteins and basement membrane
extracellular matrix proteins by promoting the expression of
inflammatory molecules, oxidative stress and the expression
of the matrix metalloproteinase 9 (MMP-9, a zinc dependent
endopeptidase; reviewed in Yong et al., 1998; Zidovetzki et al.,
1998; Weiss et al., 1999; Pu et al., 2007; Ju et al., 2009; Banerjee
et al., 2010; Song et al., 2011; Xu et al., 2012; Huang et al.,
2014). Consistent with these effects, agonists of the peroxisome
proliferator activated receptors (PPAR), a group of a nuclear
receptor proteins mediating expression of anti-inflammatory and
anti-oxidative genes, reduce Tat mediated BBB disruption in mice
(Huang et al., 2014).
The level of BBB damage may vary depending on the Tat
sequence variant found in different clades of the virus. Tat from
the HIV-1 B subtype and Tat from isolates recovered from
patients diagnosed with advanced HAD proved the most potent
in disrupting the BBB (Figure 1B).
Of the molecules present on cells of the BBB that change upon
exposure of Tat protein, P-glycoprotein (P-gp) is critical, since it is
a pump involved in the transport of small molecule compounds
out of the brain. Interestingly, the efflux function, expression
and promoter activity of P-gp are up-regulated by Tat (Zhong
et al., 2010). This may help explain why HIV-infected individuals
maintained on suppressive therapy present low levels of ART in
the brain (Gimenez et al., 2004; reviewed in Miller et al., 2008),
with up-regulated P-gp removing ART from the CNS. A better
understanding of the mechanism of action of Tat on P-gp may
offer solutions to improve the efficiency of ART in the brain
reservoir of HIV, not only for the enhancement of ART crossing
the BBB, but also for improving the anti-viral performance of
immune cells that express this protein (reviewed in Owen and
Khoo, 2004).
Tat, Glial Cells, and Neuroinflammation
Markers of gliosis have been found in vitro after treatment of
cells with either Tat or its neurotoxic domain. The same is true
in vivo in the brain and CSF of HAD-affected individuals (Gallo
et al., 1989; Tyor et al., 1992; Glass et al., 1993; Wesselingh et al.,
1993; Philippon et al., 1994; Jones et al., 1998; Shi et al., 1998;
Bruce-Keller et al., 2003; Kim et al., 2003; Turchan-Cholewo et al.,
2009a,b; Puccini et al., 2015). Indeed, Tat induces the expression
of important pro-inflammatory cytokines such as tumor necrosis
factor a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-
6) (Ambrosino et al., 1997; Chen et al., 1997; Zidovetzki et al.,
1998; Nath et al., 1999; Buscemi et al., 2007; reviewed in Li
et al., 2010; Williams et al., 2010; Yang et al., 2010; Zhao et al.,
2014; Mediouni et al., 2015), which make strong contributions
to the development of an inflammatory neuropathology. For
instance, TNF-a is associated with increased HIV-1 replication,
NMDA receptor neurotoxicity and BBB disruption (Wright et al.,
1988; Merrill et al., 1989; Stone, 1993; Fine et al., 1996; Heyes
et al., 1996; Nuovo and Alfieri, 1996; Bezzi et al., 2001; Smith
et al., 2001; reviewed in Brabers and Nottet, 2006; Buscemi et al.,
2007; Wang et al., 2008; Zhong et al., 2008; Ju et al., 2009;
Kiebala et al., 2010;Kiebala andMaggirwar, 2011). Likewise, IL-1b
up-regulation, which leads to the transcription of several pro-
inflammatory cytokines and chemokines, has been correlatedwith
the severe neurologic symptoms of HAD patients (Gallo et al.,
1989; reviewed in Allan et al., 2005; reviewed in Moynagh, 2005;
reviewed in Brabers and Nottet, 2006). In the pathway that leads
to Tat up-regulation of these two pro-inflammatory cytokines,
targeting of the protein-tyrosine phosphatase (PTP), orCD45, was
shown to attenuate microglia activation, suggesting a promising
drug target (Jin et al., 2012). Additionally, elevation of IL-6
levels was reportedly associated with increased BBB permeability
(Zidovetzki et al., 1998) and HIV replication (reviewed in Li
et al., 2010). Tat-induced expression of inflammatory cytokines
was also shown to involve other potential targets, such as the
Ankyrin-rich membrane spanning protein (ARMS/Kidins220)
in microglia cells (Singh et al., 2015) and the regulator of
microglial phagocytosis (Leucine-rich repeat kinase 2; Marker
et al., 2012).
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In addition to the effect on cytokines, Tatmodulates chemokine
pathways in microglia, inducing neuroinflammation and changes
in BBB permeability. Tat may bind to chemokine receptors
through its cysteine/ZnF domain (a chemokine like sequence),
thereby inhibiting the expression of CX3CR1 by suppressing a
NF-kB-YY1 pathway, or inducing the expression of the potent
chemoattractant chemokine MCP-1 (Fuentes et al., 1995; Albini
et al., 1998; Weiss et al., 1999; Eugenin et al., 2003; Sheng et al.,
2003; Bethel-Brown et al., 2011; Duan et al., 2014; Tewari et al.,
2015). However, the induction MCP-1 by Tat may result in a
complicated mode of action, since it has also been shown that
MCP-1 protects both neurons and astrocytes from NMDA or
Tat-induced apoptosis (Eugenin et al., 2003).
Tat and Apoptotic Pathways
As Tat influences processes of excitotoxicity, neuroinflammation
and oxidative stress, it also modulates intrinsic cellular apoptotic
pathways to variably promote both cellular death or protection.
Apoptosis induced by Tat may be triggered by different
mechanisms such as the disturbance of microtubule functions,
changes of mitochondrial activity, reduction of the activity of
the tumor suppressor p53 (involved in neuronal differentiation
and survival), induction of reticulum stress, or triggering of
the complex LRP/postsynaptic density protein-95/NMDA
receptor/neuronal nitric oxide synthase (nNOS) at the neuronal
membrane (reviewed in Roshal et al., 2001; Chen et al., 2002;
Campbell et al., 2004; Pourroy et al., 2004; de Mareuil et al.,
2005; Eugenin et al., 2007; Norman et al., 2007; Darbinian et al.,
2008; Lecoeur et al., 2012; Liu et al., 2014; Ma et al., 2014b). On
the other hand, infected cells from HIV infected patients Tat
plays a critical role inducing pathways that inhibit autophagy,
phagocytosis, or the expression of MHC molecules, as well as
up-regulation of p73 (Chehimi et al., 1996; reviewed in Huigen
et al., 2004; Amini et al., 2005; Saunders et al., 2005; reviewed in Li
et al., 2010; Van Grol et al., 2010; Hui et al., 2012; Debaisieux et al.,
2015). Thus, it is conceivable that Tat may cause the death of cells
such as neurons and supportive glial subsets, while perversely
preserving host infected cells, thereby contributing to the status
of the brain as a reservoir at the cost of neurodegeneration.
METHAMPHETAMINE NEUROTOXICITY
Methamphetamine belongs to the amphetamine-type stimulant
family. Used clinically at low doses to improve behavioral and
cognitive functions after brain injury (Rau et al., 2012), MA
is a strong psychostimulant that is widely abused as a “street
drug.” Easily synthesized, relatively long lasting, and generally
inexpensive in comparison to cocaine and heroin, MA is the
second most commonly abused drug in the world (Figure 2A).
Although MA seizure has increased dramatically in the last few
years (Figure 2B), these factors have contributed to the increase
of drug-associated health problems and social burden.
Methamphetamine induces acute euphoria, the perception
of limitless energy and high libido. Physiologically, it induces
potentially lethal hyperthermia, due to both CNS and peripheral
effects (Sanchez-Alavez et al., 2014). Chronic MA abuse
leads to neuropsychiatric complications including memory
impairment, attention deficit and psychomotor decay associated
with neurotoxicity and neurological dysfunction, as well
as significant dysregulation of neurotransmitters levels.
Importantly, MA use correlates with enhanced risk-taking
behaviors that may place drug abusers at a higher risk of
exposure to infections such as Hepatitis C and HIV, each
further contributing to CNS dysfunction. The impressive
epidemiological overlap between intravenous drug use (IDU)
and the population that is HIV-positive worldwide confirms this
trend (Figure 2C).
Methamphetamine and Neurotransmitter
Modulation
Although MA modulates a broad assortment of neuro-
transmitters, MA-induced toxicity is largely attributed
to hyperactivation of the DAergic system. MA increases
extracellular DA levels, resulting in long-term degeneration of
DAergic neurons, a mechanism also responsible for the motor
impairments associated with Parkinson’s disease (reviewed in
Riddle et al., 2006). MA exposure also promotes cognitive deficits
related to DAergic neurodegeneration (reviewed in Riddle et al.,
2006). Considerable neurochemical evidence of this neurotoxicity
includes the demonstrated decrease of DAT and the activity of
TH, a decrease of degradation of DA by monoamine oxidase
(MAO), a reduction of activity and protein levels of VMAT2, and
an increase of the reverse transport of DA via the DAT into the
extracellular space (Gibb and Kogan, 1979; Zaczek et al., 1991;
Giros et al., 1996; reviewed in Riddle et al., 2006; Eyerman and
Yamamoto, 2007; Xie and Miller, 2009; reviewed in Silverstein
et al., 2011; reviewed in Coller and Hutchinson, 2012). MA
acts through the DA receptors (D1 and D2) and the TAAR1
receptor, but recent studies have also posited a role for other DA
receptors specially the D3 involved in addiction, hyperthermia
and modulation of the immune system (Ricci and Amenta, 1994;
Ricci et al., 1997, 1998; Amenta et al., 1999; Ricci et al., 1999;
Granado et al., 2011a, Ares-Santos et al., 2012; reviewed in Yu
et al., 2015).
Following the increase of extracellular DA, MA causes a rise
in striatal glutamate release (Nash and Yamamoto, 1992; Stephans
and Yamamoto, 1994; Mark et al., 2004). Glutamate receptors, the
EAAT-2 and VGLUT (the vesicular glutamate transporters, which
are in charge of transporting glutamate into synaptic vesicles),
are also involved in mediating different behaviors attributed to
MA, such as reward, hyperlocomotor activity and, to some extent,
hyperthermia (Golembiowska et al., 2003; Achat-Mendes et al.,
2012a,b; reviewed in Cisneros and Ghorpade, 2012; Crawford
et al., 2013; Herrold et al., 2013; He et al., 2014; Hiyoshi et al., 2014;
Suryavanshi et al., 2014).
Independent from the DAergic system, MA also directly
modulates the presynaptic release of glutamate in rat cultured
hippocampal primary neurons (Zhang et al., 2014). Furthermore,
serotonergic, g-amino-butyric acid-ergic (GABAergic) and
cholinergic systems are also altered by MA, highlighting the
widespread damage caused by this drug (Halpin et al., 2014;
reviewed in Northrop and Yamamoto, 2015; reviewed in Yu et al.,
2015).
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FIGURE 2 | Worldwide distribution of methamphetamine (MA) use and HIV infection. (A) Worldwide estimation of drug use in 2012 (data from the world drug
report 2014). ATS: amphetamine-type stimulants. (B) Total amount of seized drugs reported worldwide 2008–2012 (data from UNODC global synthetic drugs
assessment 2014). (C) Superimposition of maps of the prevalence of intravenous drug use (IDU, map from the world drug report 2014) in 2012 with the prevalence
of HIV infection among IDU in 2012 (numbers in white, data from the world drug report 2014), completed with the world distribution of HIV clades (data from Chan
and Kantor, 2009) and the ranking of ATS use in 2012 (numbers in red, data from the world drug report 2014). Red arrow corresponds to an increase of more than
10% in MA/amphetamine drug use in 2011–2012 in the indicated country (data from the drug world report 2014).
Methamphetamine and Oxidative Stress
Several in vivo and in vitro studies showed the increase of
cytoplasmic andmitochondrial oxidative stress markers following
acute or chronic exposition to MA (reviewed in Silverstein
et al., 2011; Sanchez-Alavez et al., 2013; Halpin et al., 2014;
Nam et al., 2014; Sanchez-Alavez et al., 2014; Solhi et al., 2014;
Walker et al., 2014; reviewed in Yu et al., 2015). Importantly,
several neurotoxicity hallmarks induced by MA are absent
in animals that express the human superoxide dismutase 1
(SOD 1) gene, or that can otherwise quickly detoxify free radicals
induced by MA (Cadet et al., 1994; Hirata et al., 1995, 1996,
1998; Deng and Cadet, 2000; Deng et al., 2001). In addition,
antioxidant treatments have shownneuroprotective effects against
MA-induced brain damage, suggesting a significant role for
oxidative stress in MA toxicity (reviewed in Chen et al., 2010;
Lecoeur et al., 2012; Barayuga et al., 2013; Koriem et al., 2013;
reviewed in Liddie et al., 2013; Shin et al., 2014). Antioxidants
are also able to prevent and reverse MA-induced hyperthermia,
and MA-associated mitochondrial changes in animal models,
suggesting that the thermal dysregulation in drug abuse, which
is also reported as a trigger of neurotoxicity, involves the
capacity of MA to induce ROS (Sanchez-Alavez et al., 2013,
2014).
The effects of MA are associated with cellular energy
consumption and increased metabolism, potentially leading to
mitochondrial dysfunction. Mitochondria functions are affected
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by the inhibition of ATP and the complex II of the electron
transport chain (Burrows et al., 2000; Brown et al., 2005),
mediated both by glutamate and NO (Brown et al., 2005).
Moreover, ROS and quinone, a product of DA oxidation, are both
known to inhibit mitochondrial enzymes associated with energy
production (O’Shea et al., 2014). Therefore, the oxidative stress
that results from MA abuse may have dramatic consequences for
mitochondria metabolic efficiency.
Interestingly, unlike Tat, MA-induced astrogliosis was
associated with the decrease of Nrf2 (Granado et al., 2011b),
suggesting that astrocytes may have a low antioxidant capacity
when exposed to MA.
Methamphetamine and Blood–Brain
Barrier Disruption
Several preclinical and clinical studies reported BBB dysfunction
by MA through different mechanisms (reviewed in Kousik
et al., 2012; Matsumoto et al., 2014; reviewed in Northrop and
Yamamoto, 2015; reviewed in Turowski and Kenny, 2015). MA-
induced oxidative stress, hyperthermia, glutamate release and
induction of inflammation combine to decrease tight junctions
and transendothelial electric resistance via oxidative stress, down-
regulate MMP expression mediated by hyperthermia, activate
glutamate receptors, and increase the release of inflammatory
cytokines as well as the expression of heat shock proteins (Ramirez
et al., 2009; reviewed in Silverstein et al., 2011; reviewed in Kousik
et al., 2012; Shah et al., 2012; Martins et al., 2013; Urrutia et al.,
2013; reviewed in Northrop and Yamamoto, 2015). In addition,
MA exposure has been correlated with a lack of the glucose-
induced energy required for tight junction assembly and in the
attenuation of brain capillary endothelial cell growth (Abdul
Muneer et al., 2011; Fisher et al., 2015). Taken together, these
mechanisms account for collective insults to the BBB that precedes
neurological symptoms associated with chronic MA abuse.
Methamphetamine, Glial Cells,
and Neuroinflammation
Modifications to the inflammatory status of CNS glial cells
caused by MA exposure have strong implications that vary from
biochemical alterations to behavioral changes. For instance, the
release of cytokines by activated glial cells followingMA exposure
is correlated with behavioral effects such as high motor activity,
MA self-administration and relapse, as well as hyperthermia
(Boven et al., 2007; reviewed in Beardsley and Hauser, 2014;
reviewed in Loftis and Janowsky, 2014; reviewed in Salamanca
et al., 2014; reviewed in Yu et al., 2015). MA-induced DA and
glutamate release can induce the activation of pattern recognition
receptors (PRRs) in microglia that were shown to activate glial
cells (Kuhn et al., 2006; reviewed in Beardsley and Hauser, 2014;
Halpin et al., 2014; reviewed in Loftis and Janowsky, 2014).
Sigma receptors on glia and neurons have been recently
implicated in MA-induced neuroinflammation. The sigma
receptor is a chaperone protein at the endoplasmic reticulum
that controls calcium signaling through the inositol triphosphate
receptor. Various sigma receptor antagonists with different
characteristics and potency have been characterized, and proven
effective against neuroinflammatory activity (Kaushal et al., 2013,
2014; Zhang et al., 2015).
It has been suggested that voltage-gated potassium channels
(Kv) are involved in neuronal damage as well as microglial
function. Indeed, Kv1.3 is a major K+ channel expressed in
microglia that has been previously involved in MA-induced
microglia damage. MA significantly increases outward K+
currents and Kv1.3 antagonists increase microglial viability,
while also decreasing the expression of neurotoxins and pro-
inflammatory cytokines from these cells (Wang et al., 2014).
Interestingly, the pattern of microgliosis in individuals with a
history of MA addiction has been shown to persist for at least
2 years into abstinence (Sekine et al., 2008). Likewise, astrocytes
remain reactive up to 30 days followingMAexposure. It is possible
this is initially beneficial, turning maladaptive over time. In the
short term, these effects may serve as a protection mechanism
against MA-induced neurotoxicity (Hebert and O’Callaghan,
2000; Friend and Keefe, 2013; Robson et al., 2014). The release
of neurotrophic factors, anti-inflammatory cytokines, and radical
scavengers by glial cells to protect neurons from MA, have also
been reported (reviewed in Beardsley and Hauser, 2014).
Methamphetamine and Apoptotic
Pathways
The interaction between the excitotoxicity, oxidative stress,
neuroinflammation and BBB disruption results in significant
neuronal death in DA-rich regions (reviewed in Coller and
Hutchinson, 2012; reviewed in Loftis and Janowsky, 2014;
reviewed in Salamanca et al., 2014; reviewed in Yu et al., 2015).
The mechanisms of apoptosis can be either caspase-dependent or
-independent (Jayanthi et al., 2004). Even though MA-mediated
neuronal apoptosis is very well documented, the apoptosis of
other cells in the brain is less clearly established (Deng et al.,
2001; Jayanthi et al., 2004; Halpin et al., 2014). MA induces the
death of glial and oligodendrocytes through caspase-dependent
pathways (Genc et al., 2003; Jumnongprakhon et al., 2014).
Melatonin has been shown to rescue glial cells from death
(Jumnongprakhon et al., 2014), an effect that might be anticipated
because melatonin serves several immune-related functions such
as the modulation of immune cell numbers, inhibition of pro-
inflammatory cytokines, increased neurogenesis and a reduction
of adhesion molecules (reviewed in Maldonado et al., 2009).
As such, melatonin was suggested as a potential candidate to
treat mental disorders and to possess potential in MA recovery
therapies (reviewed in Maldonado et al., 2009).
On the other hand, MA was also associated with the
autophagy process to protect neurons and endothelial cells
(Castino et al., 2008; Fornai et al., 2008; Lin et al., 2012; Ma
et al., 2014a). Interestingly, caffeine increasesMA induced toxicity
in neuroblastoma cell lines by inhibiting this autophagy process
(Sinchai et al., 2011; Pitaksalee et al., 2015).
TAT AND METHAMPHETAMINE
NEUROTOXICITY
It is not surprising that a positive correlation exists between
worldwide MA drug statistics (World drug report 2014) and the
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prevalence of HIV among intravenous drug users (Figure 2C).
Interestingly, there is an increased tendency to MA/amphetamine
consumption in countries that are predominantly affected with
HIV-1 B subtype (Figure 2C), reported to be more neurotoxic
(Figure 1B). Below we review some of studies that show Tat
neurotoxicity enhanced by MA co-incubation.
Tat/Methamphetamine and HIV Replication
One important activity of MA in HIV disease progression is the
ability to enhance viral replication. MA was shown to activate the
promoter of HIV-1 in microglia cells, which Tat synergistically
amplifies (Wires et al., 2012).
Methamphetamine dysregulation of the DA system augments
viral production in different immune cells by promoting HIV
entry and HIV transcription (Rohr et al., 1999a,b; Reynolds et al.,
2007; Liang et al., 2008; Toussi et al., 2009; Marcondes et al.,
2010; Nair and Saiyed, 2011; reviewed in Purohit et al., 2011).
A review by Purohit et al. (2011) nicely illustrates the effects of
DA in HIV transcription caused by oxidative stress and NF-kB
activation in the presence of drugs of abuse in the brain (reviewed
in Purohit et al., 2011). Inhibition of phagocytosis, disruption of
pH and the reduced expression of Toll-like receptor 9 have each
been proposed as mechanisms to explain the MA promotion of
spreading HIV infection (Talloczy et al., 2008; Cen et al., 2013).
In turn, the MA-induced elevation in DA levels seems to induce
the migration of activated monocytes into the brain in the context
of HIV (reviewed in Gaskill et al., 2013; Coley et al., 2015). This
finding may be also correlated to the ability of MA in non-human
primate to up-regulate C-C chemokine receptor type 5 (CCR5),
the co-receptor for viral entry, in microglia cells, and in brain-
derived macrophages which otherwise do not exhibit a classical
inflammatory phenotype based on surface markers (Marcondes
et al., 2010).
An interesting pathway with ties to the neuroinflammatory
process triggered by MA that modulates infection is the Wnt/b-
catenin signaling cascade, which regulates the survival process
of neurons and astrocytes. In fact, astrocytes are the primary
source of Wnt ligands, triggering the Wnt signaling cascade
that mediates anti-inflammatory responses, neuroprotection and
neurogenesis (Sharma et al., 2011). It has been reported that the
Wnt/b-catenin/transcription factor 4 signaling pathway inhibits
HIV replication in astrocytes. Co-incubation of primary human
astrocytes with Tat andMA leads to an increased down-regulation
of the Wnt signaling by more than 50% compared to the activity
of MA or Tat alone. Given the additive effect of MA and Tat, it
was suggested that the toxins may be engaging distinct pathways
(Sharma et al., 2011).
Tat/Methamphetamine
and Neurotransmitters Modulation
The effects of Tat and MA on neurotransmission have been
described primarily in the context of the DA and GLUTergic
systems. Cooperative effects of Tat and MA have been shown
to enhance the DA mediated amplification of viral replication
in correlation with the enhanced motor-stimulant response to
a recurrent exposure to MA, a demonstration of behavioral
sensitization (Liu et al., 2009). Moreover, Tat and MA showed
in vivo a synergetic effect on the death of striatal DA terminals
(Maragos et al., 2002; Cass et al., 2003; Theodore et al., 2006b,d;
reviewed in Theodore et al., 2007).
Pre-pulse inhibition (PPI) is a neural mechanism in which
a weaker pre-stimulus (pre-pulse) reduces the reaction to a
following strong startling stimulus (pulse), and is used to measure
adaptive inhibition mechanisms. This is thought to be a measure
of sensorimotor gating and deficits have been reported in
schizophrenia (Bertrand et al., 2014).
Patients with HAND demonstrate deficits in PPI responses not
observed in HIV-positive participants without neurocognitive
impairment (Greenwood et al., 2007). Similarly, intra-
hippocampal infusion of Tat protein disrupts acoustic startle
response and PPI in rats (Nath and Steiner, 2014). Among adult
HIV-1 transgenic rats (that express seven of the nine clade B
HIV-1 genes), Tat has a synergistic role in the increase of the
MA-mediated disruption of PPI, an effect attributed to its ability
to decrease TH while increasing MAO (Moran et al., 2012).
Together, these findings suggest disruptions of DAergic signaling
with behavioral and cognitive consequences.
In the GLUTergic system, the combination of MA and Tat
was shown to be additive in enhancing the disruption of EAAT-
2 in astrocytic cells. This leads to elevated glutamate levels
in the synaptic clefts and a synergistic increase in midbrain
neuronal death in vitro, in a process that requires both D1 and
NMDA-receptors (Aksenov et al., 2012; reviewed in Cisneros and
Ghorpade, 2012).
Tat/Methamphetamine and Oxidative
Stress
Co-incubation of Tat and MA in cell culture in vitro has an
additive effect promoting oxidative stress (Langford et al., 2004).
Likewise, the combination in vivo results in a synergic/additive
activation of redox system-regulated transcription factors, the
increased expression of the intracellular adhesion molecule-1
(ICAM-1) gene, and of cytokines (TNF-a and IL-1b) in some
brain regions (Flora et al., 2003). Tat and MA also have an
additive effect in decreasing antioxidant enzyme levels (Banerjee
et al., 2010). Other studies have shown that the combination
of the HIV-1 envelope glycoprotein 120 (gp120) with Tat/MA
also has the capacity of synergistically reducing the expression
of tight junction proteins through a mechanism that seems to be
dependent on oxidative stress, resulting in an impairment of the
BBB (Banerjee et al., 2010). This report also demonstrates the
possible synergy between the viral proteins in the induction of
oxidative stress (Banerjee et al., 2010). On the other hand, a recent
study has shown no significant concerted effects between HIV
and substance of abuse in the increase of oxidative stress markers
detected in the CSF of HIV-positive subjects, with or without
substance use disorders (Panee et al., 2015). The differences
between these studies may be due to different levels of Tat and/or
MA used in the in vitro experiments and models, particularly in
comparison to howmuchTat is present in patients and their rate of
MA usage. Tat in the serum of HIV-infected patients was detected
at about 40 ng/ml (Xiao et al., 2000), and the concentration ofMA
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in postmortem brains of chronicMA abusers is reportedly around
0.8–1 mM (Talloczy et al., 2008). However, relatively little work
has been done on this topic, and the magnitude of the progression
of HIV infection, the frequency of drug use, the composition
of ART and the sensitivity of the assays may all influence the
outcome of these studies.
Tat/Methamphetamine and Blood–Brain
Barrier Disruption
Tat and MA synergistically and additively alter the BBB through
the increase of cell adhesion molecules (ICAM-1), the decrease
of the tight junction proteins and induction of MMP (Flora
et al., 2003; Conant et al., 2004; Banerjee et al., 2010). Moreover,
Kass et al. (2010) reported that MA-induced hyperthermia was
enhanced in HIV transgenic rats (Kass et al., 2010), consistent
with hyperthermia-induced BBB permeability (reviewed in
Northrop and Yamamoto, 2015). It has been proposed that low
non-toxic doses of Tat and MA could potentially be helpful in
temporarily reducing the BBB permeability to enhance the access
of antiretrovirals to the CNS (reviewed in Turowski and Kenny,
2015).
Tat/Methamphetamine, Glial Cells,
and Neuroinflammation
As previously mentioned, Flora et al. (2003) showed that co-
administration of Tat andMA resulted in the higher expression of
the pro-inflammatory cytokines TNF-a and IL-1b, as well as the
adhesion molecule ICAM-1 in several mouse brain regions (Flora
et al., 2003). Theodore et al. (2006c) confirmed the involvement of
TNF-a in depletion of DA levels, using a double KO for TNF-aR1
and TNF-aR2. The induction of TNF-a was also associated with
a greater loss of hippocampal neurons (Theodore et al., 2006c,d).
A cytokine array performed on rat striatal tissue treated with a
combination of MA and Tat revealed synergistically higher levels
of MCP-1, timp metallo-peptidase inhibitor 1 (TIMP-1), and IL-
1a. This activity was absent in MCP-1 KO mice, highlighting
the importance of MCP-1 in Tat/MA neurotoxicity (Theodore
et al., 2006a). These findings strongly suggest a crucial role for
cytokines in mediating the interactions between MA and Tat in
HIV-associated neurotoxicity.
Sharma et al. (2011) previously described the additive effect
of Tat and MA in down-regulating the Wnt/b-catenin survival
pathway (Sharma et al., 2011). In that study, the authors found that
unlike Tat, MA also down-regulated NF-kB reporter activity, and
as expected, decreased MCP-1 and IL-6 mRNAs. When Tat and
MA were used in combination, the reduction of NF-kB reporter
activity and MCP-1 mRNA persisted, but IL-6 expression was
normalized. This seeming discrepancy could be explained by the
fact that Tat can transactivate the IL-6 promoter by binding to IL-
6 leader RNA (a stem loop structure located at the 50-terminal
region of the IL-6 mRNA) and by interacting and increasing the
CAAT enhancer-binding protein (C/EBP) DNA binding activity
(NF-IL-6) at the IL-6 promoter (reviewed in Li et al., 2010).
Together, this suggests that the effect of both toxins together is not
always positively correlated, as each toxin could trigger different
pathways and produce unexpected phenotypes.
Tat/Methamphetamine and Apoptotic
Pathways
The cooperation between Tat and MA in triggering BBB
permeability, oxidative stress and increased viral replication may
explain the severity of HAD symptoms in HIV-infected MA
abusers, as compared to non-drug abusing patients (Nath et al.,
2001; Sporer et al., 2005; reviewed in Ferris et al., 2008; reviewed
in Purohit et al., 2011; reviewed in Silverstein et al., 2011; reviewed
in Strazza et al., 2011; reviewed in Purohit et al., 2013; reviewed
in Hauser and Knapp, 2014). This is confirmed in animal studies
using the fully replicating virus in combination withMA, showing
greater alteration of cognitive and locomotor behavior when
compared with either treatment alone (Liu et al., 2009; Kass et al.,
2010; reviewed in Silverstein et al., 2011; Kesby et al., 2015), an
effect mediated by inflammation and oxidative stress processes
(Maragos et al., 2002; Theodore et al., 2006a,b,c,d; Banerjee et al.,
2010). The cognitive and locomotor decay may also be explained
by the synergic activity of Tat andMA in triggering autophagy and
apoptosis mechanisms. For instance, in presence of Tat and MA
an increase of autophagosomes and/or multilamellar bodies was
observed upon death of a neuroblastoma cell line (Cai and Cadet,
2008; Qi et al., 2011).
Melatonin has been shown to rescue glial cells from death
and it was proposed to have potential in MA recovery therapies
(reviewed in Maldonado et al., 2009; Jumnongprakhon et al.,
2014). Tat was shown to up-regulate melatonin (Kaushal et al.,
2014), with potentially resulting effects that remain to be assessed.
Caveats
Throughout this review, we have discussed different mechanisms
by which Tat andMAmaymediate neurocognitive and locomotor
disorders (summarized in Figure 3). Nevertheless, these may
represent just the tip of the proverbial iceberg, as Tat is known
to have more than 775 interactions with cellular proteins, and
thus may interact with many more aspects of cell regulation (Self
et al., 2004). On the other hand, the extent ofMA-induced cellular
damage is also not fully understood (reviewed in Salamanca
et al., 2014). It should be noted that other factors such as gender,
nutrition, immunological strength and genetic variation could
significantly change the neurologic outcomes of HAND in MA
abusers.
NEUROTOXICITY BY
METHAMPHETAMINE USE AND HIV-1
INFECTION: POTENTIAL THERAPEUTICS
According to the CDC, as of 2010, the lifetime treatment cost of
an HIV infected patient in the United States was an estimated
$379,668. Moreover, the economical cost of substance abuse in
the United States in terms of health care, job loss, corruption,
imprisonment, and drug enforcement is more than $180 billion
dollars a year (2008, NIDA). Unfortunately, the negative impact
of HIV infection and drug abuse in our society is anticipated to
deepen as the combined incidence of HAND, MA use, and HIV-1
infected MA abusers increases.
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FIGURE 3 | Summary of the different effects of Tat, methamphetamine (MA) or Tat and MA in combination. Synergic activity is shown in italic and additive
effects in light gray. Light gray squares correspond to the main activity of each toxin.
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Under suppressive ART, HIV-1 patients are living longer, even
as current evidence suggests their quality of life will degrade
over time. Viral and human genetic variations, presence of latent
cells and viral sanctuaries reduce the efficacy of ART (Aksenov
et al., 2006). In addition, cofactors such as drug abuse significantly
deepen HIV-induced neurological impairments.
As such, improvingARTpenetration across the BBB remains an
important goal. The use of nano-ART (“cell-mediated medication
delivery”; reviewed in Gendelman and Gelbard, 2014) or the
use of intranasal delivery (reviewed in Hanson and Frey, 2007),
have shown improved efficiency in that regard. The addition
to ART of adjunctive therapies targeting the excitotoxicity,
inflammatory or anti-oxidant systems is also being explored.
Individually targeting Tat orMA is also another viable alternative.
There are currently several ongoing clinical trials testing these
approaches with MA-abusing HIV-1 patients to assess the
inhibition of neurocognitive degradation or the decrease of MA
use.
Current Clinical Trials in HIV Infected
Methamphetamine Users: Adjunctive
Therapies
Minocycline, a tetracycline antibiotic currently used to treat
bacterial infections, is a potentially exciting therapeutic agent
to treat brain disorders including HAND (Chen et al., 2000;
Du et al., 2001; Sanchez Mejia et al., 2001; Arvin et al., 2002;
Van Den Bosch et al., 2002; Wu et al., 2002; Metz et al.,
2004). Minocycline possesses several therapeutic indications
including antioxidant, anti-inflammatory, anti-viral, and anti-
addictive proprieties, and it crosses the BBB. Using cultured
primary macrophages and lymphocytes in vitro, minocycline has
been shown to prevent NMDA-induced microglial proliferation
and activation (Tikka and Koistinaho, 2001; Tikka et al.,
2001) as well as HIV and SIV replication (Zink et al., 2005).
Tested in vivo, minocycline prevents inflammation and HIV
replication in central and peripheral systems (Zink et al.,
2005; Singh et al., 2014). At the behavioral level, mouse
studies have demonstrated that minocycline decreases the
rewarding proprieties of dextroamphetamine (a stereoisomer of
amphetamine), MA and ethanol (Agrawal et al., 2011; Sofuoglu
et al., 2011; Fujita et al., 2012). Moreover, minocycline improves
cognitive deficits associated with exposure to phencyclidine
(NMDA receptor antagonist) or MA (Fujita et al., 2008;
Mizoguchi et al., 2008).
Minocycline has been tested in three clinical trials
(NCT00855062; NCT01064752; NCT00361257) related to
HIV-1-associated cognitive impairments. In the only results
available to date, the phase II clinical trial with minocycline
(NCT00361257) showed that it was safe and well-tolerated by
individuals with HAND. However, no cognitive improvement
was observed (Sacktor et al., 2011). Intake of minocycline only
resulted in a decrease in lipid markers of oxidative stress (Sacktor
et al., 2014), a disappointing result given the promise of preclinical
studies.
Ibudilast (AV-411 or MN-166) is a non-specific
phosphodiesterase inhibitor, used in Japan to treat ischemic
stroke and bronchial asthma (Gibson et al., 2006). Ibudilast
inhibits the activation of glial cells and the expression of
macrophage migration inhibitor factors (Suzumura et al., 1999,
2003; Cho et al., 2010). It was shown to attenuate microglia
activation by inhibiting the expression of pro-inflammatory
cytokines, inhibiting markers of oxidative stress and increasing
the secretion of anti-inflammatory mediators, which prevent
neuronal death and white matter injury in vivo (Wakita et al.,
2003; Mizuno et al., 2004).
Interestingly, ibudilast inhibits Tat mediated TNF-a expression
by microglial cells (Kiebala et al., 2010; Kiebala and Maggirwar,
2011). It also inhibits Tat induced HIV-neuronal loss in vitro in
the presence or absence of drugs such as morphine (Kiebala and
Maggirwar, 2011; El-Hage et al., 2014). Moreover, ibudilast was
reported to significantly inhibit HIV replication in microglia cells
(El-Hage et al., 2014).
Ibudilast also effectively protects against the glial activation
responsible for modulating MA-induced behaviors, such as
hyperlocomotion activity and MA self-administration, as well as
MA relapse caused by stress or re-exposure to MA (reviewed in
Caputo et al., 2009; Beardsley et al., 2010; Snider et al., 2012, 2013).
Ibudilast and an Ibudilast-analog that is ineffective at inhibiting
phosphodiesterase, similarly suppressed MA self-administration
in rats (Cho et al., 2010; Snider et al., 2013), raising questions over
the mechanism though which ibudilast works.
Currently, there are 10 clinical trials testing ibudilast. Of these,
NCT01217970 is a completed phase I clinical trial demonstrating
the safety of the compound in combination with MA, whereas
NCT01860807 is an ongoing phase II trial on HIV-1 patients.
Other Adjunctive Drugs
Additional FDA approved compounds, currently effective for
others brain disorders have been used in clinical trials for reducing
MA use in HIV-1 patients such as aripiprazole, mirtazapin, and
naltrexone.
Aripiprazole, which is a partial agonist at D2 receptors, is an
antipsychotic used in the treatment of schizophrenia, bipolar
disorder, depression and autism. It presented high toxicity when
used in combination with ritonavir-boosted ART and cytochrome
P450 inhibitor, reinforcing the need for caution when choosing
the dosage and ART combination (Aung et al., 2010). In addition,
depending on the dosage Aripiprazole has also been shown to
increase MA-induced reward (Newton et al., 2008). In 2014, a
phase II clinical trial (NCT00497055) was completed to test its
efficacy to decrease the use of MA by HIV patients. However, the
results are not yet available.
Mirtazapine, an antidepressant inhibitor of serotonin receptors,
was reported to participate in the reduction of progressive
multifocal leukoencephalopathy in one HIV-1 infected male
(reviewed in Lasso and Ceron, 2012) and to reduce depression
(Elliott and Roy-Byrne, 2000). It was used in a phase II trial in a
cohort of HIV-1men, which were actively usingMA. In this study
(NCT00497081), mirtazapine reduced MA usage and sexual risk.
Naltrexone, an opioid antagonist, was recently tested in a
phase II trial (NCT01822132) in MA-using HIV patients to
assess its ability to diminish MA-induced impulsive decision
under observationwithmagnetic resonance imaging to determine
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functional correlate changes in brain. The results of this trial have
not yet been made public.
Phase II clinical trials have been performed with this
compound (NCT01449565; NCT00984360) for MA dependence
on a cohort of men who have sex with men, due to the high
percentage of this population in HIV infected MA abusers
(NCT01449565), as well as on a cohort of individuals exhibiting
the mutation A118 to G118 on the mu opioid receptor gene
(NCT00984360). This mutation was shown to increase MA,
alcohol and heroin addiction (Kuppuswamy et al., 1989; reviewed
in Jeang et al., 1999; Peloponese et al., 2000; Chen et al., 2002;
reviewed in Campbell and Loret, 2009). NCT00984360 was
completed but the results are still not available, whereas, the
NCT01449565 trial is still recruiting participants at the time of this
review. In 2015, a study showed that naltrexone decreased the cue-
induced craving and subjective responses toMA (Ray et al., 2015).
This activity of the naltrexone had previously been observed
with amphetamine and cocaine (Jayaram-Lindstrom et al., 2004,
2008a,b; Comer et al., 2013).
In parallel, several trials based on themanagement of HIV/MA
are still ongoing1.
Promising Candidates
BBB alteration, excitotoxicity, oxidative stress, neuro-
inflammation and apoptosis all result from the disruption
of different physiological pathways by Tat and/or MA. The review
of Rumbaugh et al. (2008) describes different pathways involving
Tat in HAND, which are mostly used in MA activities (reviewed
in Rumbaugh et al., 2008). Therapeutically targeting cellular
pathways requires using caution with dosages, as normally
expressed human proteins are involved. Alternatively, one can
physically target each toxin individually, which may be a less
cytotoxic alternative.
Tat
Triptolide and didehydro-Cortistatin A (dCA), target the N-
terminus and the basic domain of Tat respectively. These are
currently the most promising Tat-targeting compounds, with an
activity in the nanomolar concentration range.
Triptolide
Triptolide, is a diterpenoid epoxide isolated from Tripterygium
wilfordii, which inhibits HIV-1 transcription by accelerating Tat
degradation. Triptolide was described to have anti-inflammatory,
immunosuppressive and anti-tumor properties (Wan and Chen,
2014). It is currently in a phase III clinical trial (NCT02219672),
being tested in combination with ART on HIV-1 infected
Chinese individuals for its ability to reduce the HIV-1 reservoir
size.
Didehydro-Cortistatin A
Didehydro-Cortistatin A, is an analog of a natural steroidal
alkaloid isolated from a marine sponge, Corticium simplex.
It inhibits Tat-mediated transactivation of the HIV integrated
1https://clinicaltrials.gov/ct2/results?term= hiv+methamphetamine&Search
+Search
FIGURE 4 | Potential approaches for the treatment of
Tat/methamphetamine toxicity. The optimization of ART blood–brain
barrier penetration may be achieved though a better route of administration,
using carriers, or by including adjunctive therapy.
provirus by binding specifically to the TAR-binding domain of Tat
(basic region; Mousseau et al., 2012; reviewed in Mousseau et al.,
2015). dCA promotes sustained silencing of the HIV promoter
without viral rebound even in the absence of ART in vitro. dCA
was also shown to inhibit Tat induced neuroinflammation of
astrocytes in vitro, as well as Tat-induced cocaine potentiation in
vivo (Mediouni et al., 2015).
For currently ongoing clinical trials for Tat vaccines2.
Methamphetamine
Passive and active immunizations
Passive and active immunizations against drugs of abuse are
expected to slow down entry of the drug of abuse inside the
brain thus preventing drug-associated behaviors. MA vaccines are
still in preclinical development and promote low and variable
level of antibodies production with moderate affinity for MA
(Hauber et al., 1989; Mabrouk et al., 1991; Sabatier et al., 1991;
Mousseau et al., 2012; Hambuchen et al., 2015). Research based
on conjugate vaccine and adjuvant optimization should enhance
the efficiency of these vaccines. Passive immunization with
the human-mouse chimeric monoclonal antibody, mAb7F9, is
already in more advanced stages of development (Hambuchen
et al., 2015). Mab7F9 was reported to specifically bind to MA
in the nanomolar range and mediate MA clearance (Laurenzana
et al., 2014; Stevens et al., 2014). mAb7F9 attenuated MA induced
hyper-locomotion even after irregular treatment and challenge
with higherMA doses (Hambuchen et al., 2014; Laurenzana et al.,
2014). It also partially reduced addiction-related behavior (Harris
et al., 2015). Combination of MA hapten-conjugate vaccine to
this antibody for 4 months reduced the presence of MA in the
brain (Hambuchen et al., 2015). In 2014, this mAb was the first
MA mAb to be used in a phase I clinical study in MA abusers
(NCT01603147). The study was completed and confirmed the
safety of the antibody. One potential caveat of this approach is
2https://clinicaltrials.gov/ct2/results?term= tat+vaccine&Search= Search
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that patients could be expected to increase their drug intake to
overcome the effects of the antibody.
Sigma receptors
Methamphetamine and cocaine have been shown to directly
interact with sigma receptors at physiological relevant concent-
rations (Nguyen et al., 2005; reviewed in Robson et al., 2012).
Sigma receptors have been shown to be involved in MA
induced neurotoxicity through a variety of mechanisms such
as neuroinflammation, hyperthermia, apoptosis, modulation
of neurotransmitters and oxidative stress (reviewed in Kaushal
and Matsumoto, 2011). In addition, sigma receptors show no
homology to other human proteins, supporting the development
of sigma receptor antagonists therapeutics to treat MA
abuse (reviewed in Matsumoto, 2009). Several antagonists
with nanomolar affinity have been developed. For instance,
pretreatment with CM156 prevents hyperthermia and hyper-
locomotor effects of MA as well as monoamine depletion in mice
(Kaushal et al., 2011b), whereas AZ66 has been shown to prevent
both MA-induced locomotor stimulation and the behavioral
sensitization resulting from repeated MA administration in
mice (Seminerio et al., 2012). Recently, SN79, which has been
shown to have good “drugable” proprieties (Kaushal et al.,
2011a), has mitigated MA-induced oxidative stress (Kaushal
et al., 2014), apoptosis (Kaushal et al., 2011a), neuroinflammation
(astrogliosis and microgliosis; Robson et al., 2013, 2014),
hyperthermia (Kaushal et al., 2013, 2014), and neurotransmitters
modulation (Kaushal et al., 2013). Moreover, SN79 also reverses
cocaine-induced convulsions, locomotor activity and prevents
sensitization to cocaine (Kaushal et al., 2011a). However, at higher
doses, SN79 induces sedation andmotor incoordination (Kaushal
et al., 2011a). Currently, none of the sigma receptors antagonists
are clinically tested in HIV-infected MA abusers or MA abusers
cohorts.
Caveats
Finding the ideal therapy to treat HAND on the increasingly
aging population of HIV-infected individuals, drug abusers in
particular, is a significant challenge, especially with restricted
animal models that fully reflect both HAND and drug abuse
toxicity. The ideal therapy should block the pleiotropic activities
of the toxic agent(s) without cell-associated toxicity, penetrate
the brain or retain the toxic agent in the blood stream
(e.g., antibodies), have low posology, present a high threshold
for resistance development, and importantly, be inexpensive.
Personalized therapeutic strategies may also be envisaged, given
the human genetic variation (e.g., the mu opioid mutation A118
to G118, the HIV-1 co-receptor CCR5 32 deletion), drug of
abuse-induced epigenetic variations and HIV-1 genome variation
(Kuppuswamy et al., 1989; reviewed in Jeang et al., 1999;
Peloponese et al., 2000; Chen et al., 2002; Daily et al., 2006; Li
et al., 2008; reviewed in Campbell and Loret, 2009). However,
the cost of these strategies may be a hurdle. The combination
of potent specific compounds (and/or immunizations) to ART
could constitute a first step in the treatment of HAND (see
Figure 4, for an overview of pathways and potential therapeutic
tools).
CONCLUSION
Although the biological effects of MA abuse and Tat protein have
been extensively studied in the past, the result of their interaction
is still not fully understood.
Methamphetamine abusers exhibit drug-related risk behaviors,
such as needle sharing andunsafe sexual practices that increase the
risk of acquiring an infectious disease. MA was shown to enhance
HIV-1 replication, which may explain the rapid progression to
AIDS of HIV infectedMA users. On the other hand, Tat increases
drug reward, which may partially explain the higher frequency of
drug users in the HIV population.
Tat and MA act on homologous pathways, synergistically or
additively, disturbing the same biological processes, including
neurotransmitter pathways, inflammation, oxidative stress, and
apoptosis. The outcome of this cross-interaction results in varying
degrees of neurocognitive and locomotor disorders, that depend
on patient complexity (reviewed in Valderas et al., 2009), HIV
clade and drug use frequency. Compounds that target cellular
pathways used for either Tat or MA-mediated cellular and
behavioral activities, have the potential to reduce damage from
both agents. Addition of these specific adjunctive compounds to
ART is the most accepted treatment approach for HIV infected
MA users. In addition, efforts on drug and HIV education and
prevention, should be continuously provided.
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